TY - JOUR
T1 - Dose-response relationship between inorganic arsenic exposure and lung cancer among arseniasis residents with low methylation capacity
AU - Hsu, Kuang Hung
AU - Tsui, Ke Hung
AU - Hsu, Ling I.
AU - Chiou, Hung Yi
AU - Chen, Chien Jen
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Background: Exposure to inorganic arsenic (InAs) has been documented as a risk factor for lung cancer. This study examined the association between InAs exposure, its metabolism, and lung cancer occurrence. Methods: We followed 1,300 residents from an arseniasis area in Taiwan, determined urinary InAs metabolites, and identified 39 lung cancer cases. Cox proportional hazards model was performed. Results: The results demonstrated that participants with either the primary methylation index [monomethylarsonic acid (MMA)/InAs] or the secondary methylation index [dimethylarsenic acid (DMA)/MMA] lower than their respective median values were at a higher risk of lung cancer (HRs from 3.41 to 4.66) than those with high methylation capacity. The incidence density of lung cancer increased from 79.9/100,000 (year1) to 467.4/100,000 (year1) for residents with low methylation capacity and from 0 to 158.5/100,000 (year1) for residents with high methylation capacity when the arsenic exposure dose increased from 2 to 10 ppb to 200 ppb, respectively. The analyses revealed a dose-response relationship between lung cancer occurrence and increasing arsenic concentrations in drinking water as well as cumulative arsenic exposure (monotonic trend test; P < 0.05 and P < 0.05, respectively) among the residents with low methylation capacity. The relationship between arsenic exposure and lung cancer among high methylators was not statistically significant. Conclusions: Hypomethylation responses to InAs exposure may dose dependently increase lung cancer occurrence. Impact: The high-risk characteristics observed among those exposed should be considered in future preventive medicine and research on arsenic carcinogenesis.
AB - Background: Exposure to inorganic arsenic (InAs) has been documented as a risk factor for lung cancer. This study examined the association between InAs exposure, its metabolism, and lung cancer occurrence. Methods: We followed 1,300 residents from an arseniasis area in Taiwan, determined urinary InAs metabolites, and identified 39 lung cancer cases. Cox proportional hazards model was performed. Results: The results demonstrated that participants with either the primary methylation index [monomethylarsonic acid (MMA)/InAs] or the secondary methylation index [dimethylarsenic acid (DMA)/MMA] lower than their respective median values were at a higher risk of lung cancer (HRs from 3.41 to 4.66) than those with high methylation capacity. The incidence density of lung cancer increased from 79.9/100,000 (year1) to 467.4/100,000 (year1) for residents with low methylation capacity and from 0 to 158.5/100,000 (year1) for residents with high methylation capacity when the arsenic exposure dose increased from 2 to 10 ppb to 200 ppb, respectively. The analyses revealed a dose-response relationship between lung cancer occurrence and increasing arsenic concentrations in drinking water as well as cumulative arsenic exposure (monotonic trend test; P < 0.05 and P < 0.05, respectively) among the residents with low methylation capacity. The relationship between arsenic exposure and lung cancer among high methylators was not statistically significant. Conclusions: Hypomethylation responses to InAs exposure may dose dependently increase lung cancer occurrence. Impact: The high-risk characteristics observed among those exposed should be considered in future preventive medicine and research on arsenic carcinogenesis.
UR - http://www.scopus.com/inward/record.url?scp=85019191190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019191190&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-16-0281
DO - 10.1158/1055-9965.EPI-16-0281
M3 - Article
C2 - 28007985
AN - SCOPUS:85019191190
SN - 1055-9965
VL - 26
SP - 756
EP - 761
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 5
ER -